The effect of commercial purified soybean saponin on renin activity and blood pressure was investigated. Soybean saponin significantly inhibited human renin in vitro with IC 50 ¼ 59:9 g/ml. Orally administered soybean saponin at 80 mg/kg of body weight per day to spontaneously hypertensive rats for 8 weeks significantly decreased the blood pressure.
The renin-angiotensin system (RAS) is one of the most important blood pressure (BP) control systems in animals. 1) Renin (EC 3.4.23.15) is mainly synthesized in juxtaglomerular cells in the kidney cortex and released into the circulation system by various stimuli. This enzyme cleaves the N-terminus of angiotensinogen, yielding the 10-amino acid peptide, angiotensin I (AI). This conversion is the rate-limiting step in RAS. AI is an inactive peptide and further processed by the angiotensin-converting enzyme (ACE) to produce the octapeptide, angiotensin II (AII). AII produced directly acts on arterial smooth muscle cells to maintain BP and stimulate the synthesis and release of aldosterone from the adrenal cortex. RAS is therefore a major target for treating hypertension. Aliskiren, a novel orally effective direct renin inhibitor, has recently been approved for treating hypertension in the United States, European Union, and Japan. 2) We have already screened the human renin inhibitor from wild plants and foods, 3) and isolated soyasaponin I (also known as soyasaponin Bb), 4) a triterpenoid type of saponin, from soybean (Glycine max) as an active compound. 5) We investigated in this present study whether soybean saponin containing soyasaponin I could inhibit human renin activity in vitro, and have an anti-hypertensive effect on spontaneously hypertensive rats (SHR).
The recombinant human renin expressed in Sf-9 cells was prepared by the method of Takahashi et al. 6) Soybean saponin (Saponin from Soybeans, lot no. WKL1552, with a 90.2% crude saponin content on the manufacturer's data sheet) was obtained from Wako Pure Chemical Industries (Osaka, Japan). The customsynthesized internally quenched fluorogenic (IQF) substrate for human renin, N-methylanthranyl-Ile-HisPro-Phe-His-Leu
Ã represents a scissile peptide bond) was from Peptide Institute (Osaka, Japan).
Human renin activities were measured by using the IQF substrate method described in our previous papers. 4, 6) In brief, hydrolysis of the IQF substrate at the Leu-Val bond was spectrophotometrically determined. The increase in fluorescence intensity was measured at an emission wavelength of 440 nm upon excitation at 340 nm. The sample concentration required to inhibit 50% of renin activity under the assay condition was taken as the IC 50 value.
The animal experiments in this study were performed by Japan SLC (Shizuoka, Japan). Ten-week-old male SHR/Izm of the same body weight were bred by Japan SLC and housed in individual cages in a room maintained at 24 AE 2 C with 50 AE 10% humidity and a 12-h light-dark cycle (7:00 pm-7:00 am). The rats had free access to a fresh diet (SP diet; Funabashi Farm, Chiba, Japan) and drinking water during this period. The rats were randomly assigned to two groups (n ¼ 9) and orally administered with 2 ml/kg of body weight (80 mg dry weight/kg of body weight) per day of a soybean saponin solution or vehicle (distilled water) for 8 weeks. The food intake and body weight were measured once a week, and BP was measured once a week by the tail cuff method with a UR-5000 BP meter (Ueda Electric Works, Tokyo, Japan). The average value of three readings of systolic BP was regarded as the individual systolic BP value. The rats were sacrificed under pentobarbital anesthesia after 16 h of fasting at the end of the experimental period. Blood was collected from the abdominal aorta with a heparinized syringe, and the obtained plasma was stored at À20 C until needed for analysis. The heart, liver, and kidneys from each rat were excised and weighed. The plasma levels of glucose, total cholesterol (TC), triacylglycerol (TG), y To whom correspondence should be addressed. Tel: +81-22-717-8812; Fax: +81-22-717-8813; E-mail: shirakah@biochem.tohoku.ac.jp Abbreviations: AI, angiotensin I; AII, angiotensin II; ACE, angiotensin-converting enzyme; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressure; BUN, blood urea nitrogen; BW, body weight; HDL-C, high-density lipoprotein cholesterol; IQF, internally quenched fluorogenic; LDL-C, low-density lipoprotein cholesterol; RAS, renin-angiotensin system; SEM, standard error of the mean; SHR, spontaneously hypertensive rat; TC, total cholesterol; TG, triacylglycerol high-density lipoprotein cholesterol (HDL-C), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and blood urea nitrogen (BUN) were measured with a Dri-Chem 3500V automatic analyzer (Fujifilm, Tokyo, Japan). The concentration of low-density lipoprotein cholesterol (LDL-C) was calculated by Friedewald's formula.
7) The plasma renin activity was measured by Mitsubishi Chemical Medience (Tokyo, Japan), and the concentrations of plasma angiotensinogen and AI were assayed by commercial ELISA kits. The experimental plan for the present study was approved by the Ethics Committee for Animal Experiments of Akita Research Institute for Food and Brewing. The entire experiment closely followed the guidelines issued by the committee which strictly follows government legislation in Japan.
Each data value is presented as the mean and its standard error (SEM). Student's t-test was used to evaluate differences between the two groups studied. GraphPad Prism 5.0-J software (MDF, Tokyo, Japan) was used to analyze all data, a probability value of p < 0:05 being considered significant.
We initially investigated the dose-dependence of human renin inhibition by soybean saponin in vitro. Figure 1 shows a summary of the results obtained in the assays. The dose response was fitted to a sigmoidal model, showing that soybean saponin could act as an inhibitor of human renin with IC 50 ¼ 59:9 mg/ml. The same method as that for renin inhibition was used to measure the IC 50 value for pepstatin, a specific inhibitor of aspartic protease, as 20.4 mM, and it was reported that oleic acid and linoleic acid competitively inhibited renin activity, with IC 50 ¼ 28:3 and 37.4 mM, respectively. 8) In addition, we have previously reported that an IC 50 value of soyasaponin I for human renin of 30 mg/ml (31.8 mM), 4) while Kitagawa et al. have reported that the content of soyasaponin I in total soyasaponin of soybean was about 50%. 9) Given that other soyasaponins (e.g., soyasaponin II (also known as soyasaponin Bc)) also inhibited human renin, 10) the IC 50 value for soybean saponin for human renin appears to be reasonable.
We have previously reported that partially purified soybean saponin significantly reduced BP in SHR. 4) Soybean embryos were soaked in distilled water and heated at 121 C for 15 min. The sample was homogenized and centrifuged, and the supernatant was applied to a C18 solid-phase extraction column. This column had been washed with distilled water and 50% methanol.
The adsorbed materials were then eluted with 100% methanol. The eluate evaporated to dryness was partially purified soybean saponin which might have contained other hypotensive compounds. The major purpose of this study was to clarify whether soybean saponin had a hypotensive effect in vivo, so we then attempted to disclose the hypotensive effect of soybean saponin by using a commercially purified reagent. There was no difference in the body weight, body weight gain, and food intake between the two groups in the chronic administration experiment (Table 1) . The results from harvested tissues indicate that the weights of the heart, liver, and kidneys were no different between the two groups ( Table 1 ). The mean systolic BP of SHR orally administered with soybean saponin is illustrated in Fig. 2 . An increase in BP was observed in both groups from week 1 until the end of the experimental period, although the saponin group tended to show a lower BP value than the control group, being significantly lower in weeks 7 and 8. The respective changes of BP in the control and saponin groups from the beginning were 47 mm of Hg and 25 mm of Hg (53.2% of the control value) in week 8. Table 1 shows the plasma parameters recorded in the present experiment. The oral administration of soybean saponin did not influence TG, TC, HDL-C and glucose; however, the average LDL-C, AST, ALT, and BUN values in the saponin group were lower than those in the control group (29.4%, 31.7%, 18.2%, and 14.6% lower, respectively). The LDL-Clowering effect and liver injury-preventive effect of soyasaponin in laboratory animals have already been reported; 5, 11, 12) however, little is known about the effect of reducing the marker of kidney function (i.e., BUN) by soybean saponin. Soybean saponin may possibly protect the kidneys from hypertensive damage by reducing the BP level. We have previously reported that partially purified soybean saponin did not change the plasma levels of AST, ALT, and BUN. 4) It is thought that the reason for there being no change in some blood parameters was too little amount of saponin in the partially purified soybean saponin administered to SHR.
We have demonstrated in this study that soybean saponin inhibited human renin activity in vitro, and had an anti-hypertensive effect in vivo. It is known that there are some mechanisms for anti-hypertensive drugs to decrease BP, block the AII receptor, calcium channel or -adrenergic receptor, inhibit ACE or renin, and so on. We tested whether soybean saponin inhibited ACE; 400 mg/ml of soybean saponin did not affect the activity of ACE in vitro. It is not yet known whether soybean saponin interferes with the AII receptor, calcium channel, or -adrenergic receptor. Taken together, these results raise the possibility that an oral administration of soybean saponin can suppress the plasma renin activity and that this suppression would reduce BP in vivo. If soybean saponin had been a renin inhibitor, the renin activity and the amount of AI might be predicted to decrease in rat plasma. We then measured the plasma renin activity and the concentrations of plasma angiotensinogen and AI in SHR in week 8. Although the renin activity and angiotensinogen levels were not changed in either group, the AI level in the saponin group tended to be 27.6% lower than that in the control group, but not significantly (Table 1) . When we sacrificed the rats used Relative activity is shown as a percentage of the renin activity without soybean saponin. Each value is the mean with the standard error depicted by a vertical bar (a triplicated analysis).
for the experiment, we collected the blood sample after 16 h of fasting. A 16-h fasting period is suspected to have promoted the degradation of plasma AI by ACE and decrease the concentration of soybean saponin in the plasma, so that the renin activity did not decline. We can show at present only indirect evidence for soybean saponin suppressing the plasma renin activity in vivo, but we will attempt to obtain clearer evidence by using liquid chromatography-mass spectrometry to detect soyasaponins in the plasma, and the time-course characteristics for renin inhibition and reducing BP by soy saponin in vivo.
In conclusion, we have demonstrated that soybean saponin inhibited human renin activity in vitro, and improved hypertension in SHR. The administration of soybean saponin is suspected to be beneficial to preventing hypertension. Symbols indicate the control group (filled circles) and saponin group (filled squares). Each value is the mean with the standard error depicted by a vertical bar (9 rats per group). Mean values were significantly different from those of the control group: Ã p < 0:05; ÃÃ p < 0:01.
